In the study, 846 overweight or obese patients with diabetes were randomly assigned to at least one 1.8 mg or 3 mg of liraglutide or a placebo daily. Those that took 1.8 mg lost an average of near 5 % of their body weight , while individuals going for a placebo lost an average of 2 % of their body weight , the researchers reported. According to the scholarly research, published Aug. 18 in the Journal of the American Medical Association, 54 % of those getting the 3 mg-dosage dropped at least 5 % of their body weight, compared with more than 40 % of those on the 1 slightly. 8 mg dosage and simply over 21 % of those taking a placebo.‘This progress also factors to cellular signaling mechanisms mediated by Akt1 as being highly relevant to the biology of cannabis psychosis. This may suggest study directions for novel therapeutics for cannabis psychosis.’ Di Forti agreed, adding that ‘such findings could also help design health educational campaigns tailored to reach those young people at particular risk.’.
Christoph Kaiser, M.D., Soeren Galatius, M.D., Paul Erne, M.D., Franz Eberli, M.D., Hannes Alber, M.D., Hans Rickli, M.D., Giovanni Pedrazzini, M.D., Burkhard Hornig, M.D., Osmund Bertel, M.D., Piero Bonetti, M.D., Stefano De Servi, M.D., Hans-Peter Brunner-La Rocca, M.D., Ingrid Ricard, Ph.D., and Matthias Pfisterer, M.D.